| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 50 Number 5
Volume 50 Number 4
Volume 50 Number 3
Volume 50 Number 2
Volume 50 Number 1
Volume 49 Number 6
Earlier issues
Volume  Number 

previous article next article

Research articles

ScienceAsia 50 (2024):ID 2024080 1-7 |doi: 10.2306/scienceasia1513-1874.2024.080


Pyrroloquinoline quinone protects against doxorubicin-induced cardiotoxicity in mice by modulating Nrf2 and NF-kB activities


Hechao Wanga, Junchao Lib,*

 
ABSTRACT:     Pyrroloquinoline quinone (PQQ) is a potent antioxidant cofactor that is widely distributed in the animal and plant tissues and is considered to be an indispensable nutrient in the mammals. In the present investigation, we examined PQQ effects on doxorubicin (DOX)-induced cardiotoxicity in mice. The animals received a single 15-mg/kg intraperitoneal dose of DOX injection at day 1. A daily oral dose of 10 mg/kg PQQ were administered to the mice in the study group. Nuclear factor kappa beta (NF-kB) and nuclear factor erythroid 2related factor 2 (Nrf2) activities were measured in the nuclear fractions of cardiac tissue homogenates. Cardiac histopathology and function, as well as serum markers of cardiac injury and tissue markers of inflammation and oxidative stress were examined. PQQ improved Nrf2 activity and at the same time suppressed NF-kB activity. PQQ reduced cardiac levels of tumor necrosis factor ? (TNF?) and malondialdehyde (MDA), and elevated tissue activities of superoxide dismutase (SOD). PQQ decreased serum levels of creatinine kinase MB (CK-MB) and cardiac troponin I (cTnI), and improved histopathological indices of cardiac injury as well as cardiac function. Altogether, these findings emphasize that PQQ is protective against DOX-induced cardiotoxicity in mice by modulating NF-kB and Nrf2 pathways.

Download PDF

0 Downloads 339 Views


a Yangfang Outpatient Department, The Northern Medical District, Chinese PLA General Hospital, Beijing 100094 China
b Internal Medicine Department, Qinghe Branch Hospital of Beijing Bureau of Prisons, Beijing 100000 China

* Corresponding author, E-mail: lijunchao0910@sina.com

Received 13 Apr 2023, Accepted 10 Jul 2024